Skip to content

US · XBIT · BIOTECHNOLOGY

XBiotech Inc. (XBIT) intrinsic value and stock valuation

$1.73as of 2026-11-21 · Mkt cap 69.21M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

XBiotech Inc. DCF and intrinsic value

InvestorsCraft values XBIT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XBIT’s statements →

XBiotech Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Austin, TX 78744 xbiotech.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-45.54M
20122025
Free cash flow
-$-40.21M
20122025
Total equity
$140.4M-16.6% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$4.01M$18.4M
Operating income-$-55.69M-$-42.47M-$-37.51M-$-34.49M-$-25.08M
Net income-$-45.54M-$-38.53M-$-24.56M-$-32.9M-$-17.41M
EPSd-$-1.49M-$-1.26M-$-806.83K-$-1.08M-$-579.56K
Operating cash flow-$-39.92M-$-30.96M-$-18.73M-$-14.82M$69.4M
Capital expenditure-$-290K-$-1.3M-$-360K-$-580K-$-3.52M
Free cash flow-$-40.21M-$-32.27M-$-19.09M-$-15.41M$65.9M
Total assets$150.1M$199.1M$226.6M$246.1M$275.2M
Total debt$0.00$10.3M$0.00$0.00$0.00
Net debt-$-125.55M-$-162.43M-$-200.02M-$-157.31M-$-236.98M
Total equity$140.4M$182.3M$218.9M$240.4M$269.4M
Cash and short-term investments$125.6M$172.7M$200M$217.5M$237M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$4.01M$18.4M
Cost of revenue$1.69M$0.00$0.00$650K$5.82M
Gross profit-$-1.69M$0.00$0.00$3.36M$12.6M
Research and development expenses$47.4M$37.8M$32.9M$31.5M$28.3M
Selling, general and administrative expenses$8.29M$4.71M$4.66M$6.3M$9.39M
Other expenses-$-1.69M$0.00$0.00$0.00$0.00
Operating expenses$54M$42.5M$37.5M$37.9M$37.7M
Cost and expenses$55.7M$42.5M$37.5M$38.5M$43.5M
Interest income$5.68M$9.81M$10.4M$3.82M$470K
Interest expense$90K$810K$0.00$0.00$0.00
Depreciation and amortization$1.69M$1.75M$1.74M$2.61M$2.65M
Ebitda-$-43.53M-$-36.01M-$-22.57M-$-30.97M-$-22.81M
Operating income-$-55.69M-$-42.47M-$-37.51M-$-34.49M-$-25.08M
Total other income/expenses, net$10.4M$3.91M$13.2M$900K-$-380K
Income before tax-$-45.3M-$-38.56M-$-24.31M-$-33.59M-$-25.46M
Income tax expense$230K-$-30K$240K-$-690K-$-8.04M
Net income-$-45.54M-$-38.53M-$-24.56M-$-32.9M-$-17.41M
Weighted average shares outstanding$30.5M$30.5M$30.3M$30.4M$30M
Weighted average diluted shares outstanding$30.5M$30.5M$30.4M$30.4M$30M
Balance sheet
20252024202320222021
Cash and short-term investments$125.6M$172.7M$200M$217.5M$237M
Net receivables$360K$860K$940K$1.76M$8.95M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$127M$174.6M$201.7M$219.8M$246.9M
Property, plant and equipment, net$23.1M$24.5M$24.9M$26.3M$28.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$23.1M$24.5M$24.9M$26.3M$28.3M
Total assets$150.1M$199.1M$226.6M$246.1M$275.2M
Accounts payable$1.53M$2.22M$2.52M$2.41M$2.07M
Short-term debt$0.00$10.3M$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.93M$15.1M$6.1M$4.07M$3.45M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.8M$1.72M$1.67M$1.64M$2.34M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$9.73M$16.8M$7.77M$5.7M$5.79M
Common stock$276.7M$273.1M$271.2M$267.3M$262.3M
Retained earnings-$-136.38M-$-90.84M-$-52.31M-$-27.75M$5.15M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$830K$1.97M
Total equity$140.4M$182.3M$218.9M$240.4M$269.4M
Total investments$0.00$0.00$0.00$60.2M$0.00
Total debt$0.00$10.3M$0.00$0.00$0.00
Net debt-$-125.55M-$-162.43M-$-200.02M-$-157.31M-$-236.98M
Cash flow statement
20252024202320222021
Net income-$-45.54M-$-38.53M-$-24.56M-$-32.9M-$-17.41M
Depreciation and amortization$1.69M$1.75M$1.74M$2.61M$2.65M
Stock-based compensation$3.62M$1.75M$3.26M$5.06M$4.46M
Change in working capital$3.64M-$-1.46M$2.72M$7.6M$79.8M
Accounts receivable$570K$80K$830K$7.34M$1.73M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-690K-$-360K$90K$360K-$-510K
Net cash provided by operating activities-$-39.92M-$-30.96M-$-18.73M-$-14.82M$69.4M
Investments in property, plant and equipment-$-290K-$-1.3M-$-360K-$-580K-$-3.52M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-290K-$-1.3M$61.5M-$-63.89M-$-3.52M
Common stock issued$0.00$0.00$10K$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-75M
Net cash used for financing activities-$-10.25M$10.5M-$-10K$0.00-$-67.01M
Net change in cash-$-47.13M-$-27.35M$42.7M-$-79.68M-$-380K
Cash at end of period$125.6M$172.7M$200M$157.3M$237M
Operating cash flow-$-39.92M-$-30.96M-$-18.73M-$-14.82M$69.4M
Capital expenditure-$-290K-$-1.3M-$-360K-$-580K-$-3.52M
Free cash flow-$-40.21M-$-32.27M-$-19.09M-$-15.41M$65.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About XBiotech Inc.

        XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

        CEO
        Sushma Shivaswamy
        Employees
        85
        Beta
        0.84

        Explore

        Frequently asked questions

        What is the intrinsic value of XBiotech Inc. (XBIT)?

        InvestorsCraft does not currently publish an intrinsic value for XBIT. How the IC value is calculated.

        Is XBIT undervalued?

        InvestorsCraft does not publish an undervaluation signal for XBIT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.